Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the world’s worst pathogens. “This is a crazy idea,” Sato said.
Nelsen, managing director of ARCH Venture, had made a name and fortune off crazy ideas, but generally it was the science that sounded crazy: engineering cells to cure cancer, finding drugs to slow aging. This new idea was financially crazy. For years, biotech companies had been pulling out of infectious disease.
Sato, by then retired, had watched them retreat. Cerebral and uncompromising, she loved infectious disease, both the impact and the us-versus-them clarity of chasing a pathogen foe. She had worked on HIV and hepatitis C drugs at Biogen and Vertex, storied companies that ultimately moved on to cancer, neurology, rare disease, and autoimmunity.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.